Medical Research News

RSS

Study shows how rare but serious post-COVID-19 complication develops in children, adolescents

A multidisciplinary team from MassGeneral Hospital for Children (MGHfC), Brigham and Women's Hospital and other institutions have identified the mechanism of how an extremely rare but serious post-COVID-19 complication develops in children and adolescents.

26 May 2021

Scientists propose new strategies to find drugs that neutralize critical enzymes

Scientists from the University of Bath explore racemases and propose strategies for finding drugs that target these important enzymes.

26 May 2021

Researchers explore mechanical properties of cellular microenvironment in the body

Cells sense and respond to the mechanical properties of the cellular microenvironment in the body. Changes in these properties, which occur in a number of human pathologies, including cancer, can elicit abnormal responses from cells.

26 May 2021

Moderna's COVID vaccine proves effective against South African variant in primates

Researchers in the United States have demonstrated the efficacy of Moderna’s coronavirus disease 2019 (COVID-19) vaccine at protecting against the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in non-human primates.

26 May 2021

Kennedy Krieger Institute researcher wins NIH award for movement learning study

The National Institutes of Health (NIH) recently awarded Amy Bastian, Ph.D., PT, chief science officer and director of the Motion Analysis Lab at Kennedy Krieger Institute, with an eight-year, $4.7 million National Institute of Neurological Disorders and Stroke (NINDS) Research Program Award (N35) to support a study examining movement learning mechanisms and how this process is affected by brain damage.

26 May 2021

NFCR announces winners of 2021 Salisbury Award Competition

The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.

26 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

Modeling the risk of SARS-CoV-2 outbreaks upon lifting non-pharmaceutical interventions (NPIs)

In a paper recently uploaded to the preprint server medRxiv* by Sachak-Patwa et al. (May 22nd, 2021), mathematical models are developed to assess the probability and impact of such localized outbreaks, accounting for changing general immunity levels in the population as vaccines are distributed.

25 May 2021

Person infected with SARS-CoV-2 can transmit infection to three to five other people

What started as the preliminary analysis of routine laboratory data has since evolved into the largest-ever study of viral load levels in patients with SARS-CoV-2.

25 May 2021

Men with low testosterone levels are more susceptible to severe COVID-19

Throughout the pandemic, doctors have seen evidence that men with COVID-19 fare worse, on average, than women with the infection.

25 May 2021

Study reveals how harmless skin microbes become deadly pathogens

The bacterium Staphylococcus epidermidisis primarily a harmless microbe found on the skin and in the noses of humans.

25 May 2021

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

A team of international scientists recently conducted a randomized clinical trial to assess the safety and efficacy profiles of a novel probiotic formulation in symptomatic coronavirus disease 2019 (COVID-19) patients. The findings indicate that the probiotic formulation is highly effective in reducing symptom severity in COVID-19 patients without causing any adverse events.

25 May 2021

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world.

25 May 2021

New study may pave way for novel therapeutic strategies for COVID-19

An international and multidisciplinary team led by researchers at the University of Oxford, University of Glasgow, and University of Heidelberg, has uncovered the interactions that SARS-CoV-2 RNA establishes with the host cell, many of which are fundamental for infection.

25 May 2021

Newly identified small molecule can be used to rejuvenate the brain, counteract memory loss

Alzheimer's disease is the main cause of dementia and current therapeutic strategies cannot prevent, slow down or cure the pathology.

25 May 2021

A new model to prevent or manage caffeine withdrawal after surgery

Millions of people consume caffeine in coffee, tea, sodas and energy drinks, but when they go without, the withdrawal symptoms can include drowsiness, difficulty concentrating and intense headaches.

25 May 2021

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

A research group from Osaka University led by Professor Hisashi Arase and consisting of researchers from the Research Institute for Microbial Diseases, the Institute for Protein Research, the Immunology Frontier Research Center, the Center for Infectious Diseases, and the Graduate School of Medicine has discovered for the first time that both neutralizing antibodies that protect against infection as well as infection-enhancing antibodies that increase infectivity are produced after infection with SARS-CoV-2 by analyzing antibodies derived from COVID-19 patients.

25 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

Medical Research News

Study shows how rare but serious post-COVID-19 complication develops in children, adolescents

Scientists propose new strategies to find drugs that neutralize critical enzymes

Researchers explore mechanical properties of cellular microenvironment in the body

Moderna's COVID vaccine proves effective against South African variant in primates

Kennedy Krieger Institute researcher wins NIH award for movement learning study

NFCR announces winners of 2021 Salisbury Award Competition

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

Modeling the risk of SARS-CoV-2 outbreaks upon lifting non-pharmaceutical interventions (NPIs)

Person infected with SARS-CoV-2 can transmit infection to three to five other people

Men with low testosterone levels are more susceptible to severe COVID-19

Study reveals how harmless skin microbes become deadly pathogens

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

New study may pave way for novel therapeutic strategies for COVID-19

Newly identified small molecule can be used to rejuvenate the brain, counteract memory loss

A new model to prevent or manage caffeine withdrawal after surgery

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

Latest News